Should you buy BioCryst Pharmaceuticals (BCRX)?
Updated
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Engine methodology range
Range computation requires sufficient peer-comparable data; available for tickers with peer_count ≥3.
What the engine is tracking
- Fcf Positive Despite Gaap Loss→Stable
- Earnings Beat Streak High Magnitude→Stable
- Deep Value Forward Multiple→Stable
- +1 more pillar — see the Why tab for full reasoning
→ Full pillar scorecard with all 4 pillars + per-dimension breakdown
When this thesis breaks
Falsifiable conditions per pillar — any one trip warrants review independent of price action. Engine-derived; not personalized advice.
Falsifying conditions — when triggered, the corresponding pillar's thesis is invalidated.
- P1Earnings Beat Streak High Magnitude
Trip ifEPS surprise falls below 0% for 2 consecutive quarters.
- P2Deep Value Forward Multiple
Trip ifForward P/E expands above 25x from the current 13.3 times as earnings estimates are revised downward.
- P3Fcf Positive Despite Gaap Loss
Trip ifFree cash flow margin falls below 10% for 2 consecutive quarters from the current 30% level.
- P4Short Interest Binary Downside Risk
Trip ifShort interest rises above 20% of float from the current 15%.
How the engine reached this verdict
TrendMatrix's engine output for BioCryst Pharmaceuticals, Inc. (BCRX) is STRONG_BUY_WAIT with medium conviction, score 6.2/10 at $9.79. None of the engine's positive-conviction paths (C-quality, D-momentum) cleared their gates — the F-path HOLD reflects balanced signals rather than directional conviction.
The engine's suggested entry zone is $9.08, currently 7.8% above entry. Target $18.97, stop $8.03, asymmetric R:R 6.18. The WAIT designation reflects entry-discipline framing — chasing into the current zone compresses asymmetry, which is why the engine separates WAIT from NOW. The engine's sizing output: 0.7% of portfolio at this asymmetry level (medium-conviction tier).
On the bull side: Positive news sentiment (+0.67); Attractive valuation; Strong growth profile. On the bear side: Elevated risk factors. Active engine warnings: L3:NEWS_MOD=+1: HOLD_IF_HOLDING → STRONG_BUY_WAIT.
BUY_NOW requires asymmetry R:R climbing above the 2.5 conviction threshold (currently 6.18); the verdict flips to HOLD if overall score deteriorates by ~0.7.
For the full 10-dimension breakdown + V9 gate detail: Why TrendMatrix rates BCRX — 10-dimension breakdown →
Bull case
- ▸Positive news sentiment (+0.67)
- ▸Attractive valuation
- ▸Strong growth profile
Bear case
- ▸Elevated risk factors